Division of Vascular Surgery, Department of Surgery, University of Maryland School of Medicine, Baltimore, Md.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Md.
J Vasc Surg Venous Lymphat Disord. 2022 Jan;10(1):102-110. doi: 10.1016/j.jvsv.2021.05.007. Epub 2021 Jun 2.
Upper extremity (UE) deep vein thrombosis (DVT) is a common and increasing complication in hospitalized patients. The objective of the present study was to determine the prevalence, treatment strategies, complications, and outcomes of UE-DVT.
We performed a retrospective single-institution study of patients with a diagnosis of UE-DVT from January 2016 through February 2018 (26 months). Patients aged ≥18 years who had been admitted to the hospital and who had had positive UE duplex ultrasound findings for acute UE-DVT were included in the present study. The outcomes were in-hospital mortality, major bleeding, pulmonary embolism (PE), and recurrent UE-DVT.
Among 63,045 patients admitted to the hospital, 1000 (1.6%) had been diagnosed with UE-DVT. Of 3695 UE venous duplex ultrasound examinations performed during the study period, almost one third (27.0%) were positive for acute UE-DVT. The mean age was 55.0 ± 17.2 years, and most patients were men (58.3%), white (49.2%), and overweight (mean body mass index, 29.4 ± 10.3 kg/m). The most affected vein was the right internal jugular vein (54.8%). Most of the patients (96.9%) has been receiving venous thromboembolism prophylaxis or anticoagulation therapy at the diagnosis. Most patients (77.8%) had had an intravenous device (IVD) in place at the diagnosis. Most of the patients (84.4%) were treated with anticoagulation therapy in the hospital but only one half (54.5%) were discharged with anticoagulation therapy. In-hospital mortality was 12.1% unrelated to UE-DVT, major bleeding occurred in 47.6% of the patients during hospitalization (fatal bleeding, 1%), PE was diagnosed in 4.8% of the patients, and 0.7% were fatal. Recurrent UE-DVT occurred in 6.1% of the patients. On multivariable analysis, the risk of death was increased by older age, cancer, intensive care unit admission, concomitant lower extremity DVT, and bleeding before the UE-DVT diagnosis. The presence of an IVD increased the risk of PE and the risk of recurrent UE-DVT. The risk of major bleeding was increased by the presence of an IVD, female sex, and concomitant lower extremity DVT.
UE-DVT is a common complication in hospitalized patients (1.6%). Consequent acute PE and recurrent DVT remain important complications, as does bleeding. It is unclear whether standard thromboprophylaxis effectively protects against UE-DVT. More studies dedicated to UE-DVT are required to provide appropriate guidance on prophylaxis and treatment.
上肢(UE)深静脉血栓形成(DVT)是住院患者中常见且日益增加的并发症。本研究的目的是确定 UE-DVT 的患病率、治疗策略、并发症和结局。
我们对 2016 年 1 月至 2018 年 2 月(26 个月)期间诊断为 UE-DVT 的住院患者进行了回顾性单机构研究。本研究纳入了年龄≥18 岁、因急性 UE-DVT 而接受 UE 双功超声检查阳性的住院患者。研究结局为院内死亡率、大出血、肺栓塞(PE)和复发性 UE-DVT。
在 63045 名住院患者中,有 1000 名(1.6%)被诊断为 UE-DVT。在研究期间进行的 3695 次 UE 静脉双功超声检查中,近三分之一(27.0%)为急性 UE-DVT 阳性。平均年龄为 55.0±17.2 岁,大多数患者为男性(58.3%)、白人(49.2%)和超重(平均体重指数 29.4±10.3kg/m)。最受影响的静脉是右侧颈内静脉(54.8%)。大多数患者(96.9%)在诊断时已接受静脉血栓栓塞症预防或抗凝治疗。大多数患者(77.8%)在诊断时存在静脉内装置(IVD)。大多数患者(84.4%)在医院接受抗凝治疗,但只有一半(54.5%)出院时接受抗凝治疗。院内死亡率为 12.1%,与 UE-DVT 无关,47.6%的患者在住院期间发生大出血(致命性出血 1%),4.8%的患者诊断为 PE,其中 0.7%为致命性。复发性 UE-DVT 发生在 6.1%的患者中。多变量分析显示,年龄较大、癌症、入住重症监护病房、合并下肢 DVT 以及 UE-DVT 诊断前出血会增加死亡风险。存在 IVD 会增加 PE 和复发性 UE-DVT 的风险。存在 IVD、女性和合并下肢 DVT 会增加大出血风险。
UE-DVT 是住院患者的常见并发症(1.6%)。随后的急性 PE 和复发性 DVT 仍然是重要的并发症,出血也是如此。目前尚不清楚标准的血栓预防是否能有效预防 UE-DVT。需要更多专门针对 UE-DVT 的研究,以提供适当的预防和治疗指导。